Keeping Pace in Lung Cancer – How Would You Treat? Case-Based Learning in EGFR-Mutant NSCLC

Keeping Pace in Lung Cancer – How Would You Treat? Case-Based Learning in EGFR-Mutant NSCLC

Keeping Pace in Lung Cancer – How Would You Treat? Case-Based Learning in EGFR-Mutant NSCLC
RestartResume

Making the right choice in the first line can be the difference for patients with EGFR-mutant NSCLC. Are you keeping up by adding anti-VEGF to TKIs? 

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    FLAURA and RELAY have changed the landscape of treatment in EGFR-mutant advanced non-small cell lung cancer (NSCLC). But how do know which patients will benefit from these important advances in our knowledge of treating these cancers in the first and subsequent lines of therapy? Join Drs. Mark Socinski and John Heymach as they examine a patient case and discuss the “art” of treatment selection and sequencing of therapy. They also dive into recent advances in the dual blockade of antiangiogenics and TKIs in the frontline setting. Tune in to keep up!

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Mark A. Socinski, MD
    Executive Medical Director
    AdventHealth Cancer Institute
    Orlando, FL

    Contracted Research: AstraZeneca, Genentech, Novartis, Pfizer, Spectrum 
    Consulting Fees: AstraZeneca, Blueprint, G1 Therapeutics, Genentech, Janssen, Jazz, Merck

    Faculty:
    John Heymach, MD, PhD
    Chair, Thoracic/Head and Neck Medical Oncology
    MD Anderson Cancer Center
    Houston, TX

    Research: AstraZeneca, GlaxoSmithKline, Spectrum Pharmaceuticals
    Stock and Other Ownership Interests: Cardinal Spine, Bio-Tree
    Consulting or Advisory Role: AstraZeneca, Boehringer Ingelheim, BrightPath Biotherapeutics, Bristol Myers Squibb, Catalyst Biotech, EMD Serono, Foundation Medicine, Genentech/Roche, GlaxoSmithKline, Guardant Health, Hengrui Pharmaceutical, Janssen, Kairos Ventures, Leads Biolabs, Lilly, Mirati Therapeutics, Nexus Health Systems, Novartis, Pneuma Respiratory, Roche, Sanofi/Aventis, Spectrum Pharmaceuticals, Takeda
    Patents, Royalties, Other Intellectual Property: Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Nicole Fox, DNP, MSN-ED, RN, OCN, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
    • Ann Early has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Select treatment options for NSCLC patients with EGFR alterations in advanced NSCLC
  • Target Audience

    This activity is designed to meet the educational needs of community oncologists as well as pulmonologists, pathologists, oncology nurse practitioners, physician assistants, oncology nurses, and oncology pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this audio-based activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 11/30/2022. PAs should only claim credit commensurate with the extent of their participation in the activity. 

    This curriculum has been approved for 0.25 contact hours .025 CEUs by Global Learning Collaborative (GLC).  GLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this program is UAN JA0006235-0000-21-002-H01-P. This learning activity is audio-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant Lilly USA, LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free